|
---|
Category:Report
MONTHYEARML24018A1152024-01-19019 January 2024 Acu Msrr - Historic and Cultural Resources ML23338A2572023-12-14014 December 2023 Kairos Power LLC - Summary Record of Decision ML23333A0142023-11-27027 November 2023 Attachment F - Groundwater Tek Inc - Peer Review Study Final-1 ML23333A0172023-11-27027 November 2023 Attachment I - Chin - the Cooling Canal System at the FPL-Turkey-Point Power Station ML23229A2272023-11-0909 November 2023 Response to SRM-M230814 - Rulemaking - Final Rule - Comment Response Document - Emergency Preparedness for Small Modular Reactors and Other New Technologies ML23251A0462023-09-30030 September 2023 Technical Report - Review of Documents Related to Tank 12H Grout Formulations ML23194A1352023-09-0707 September 2023 OMB 3150-0007, Final Supporting Statement for 10 CFR Part 34, Licenses for Radiography and Radiation Safety Requirements for Radiographic Operations ML23192A7672023-08-21021 August 2023 Intercontinental Energy Corporation Final Completion Review Report Review and Approval ML22353A5992023-06-21021 June 2023 Enclosure - NMSS VLSSIR Wg Report and Implementation Guidance ML23097A1712023-05-0808 May 2023 Review of New and Potentially Significant Information for the Holtec Environmental Impact Statement for a Consolidated Interim Storage Facility for Spent Nuclear Fuel in Lea County, New Mexico ML22271A8622023-03-24024 March 2023 OMB-3150-0017 Final Supporting Statement for 10 CFR Part 30 Rules of General Applicability to Domestic Licensing of Byproduct Material ML22320A0752023-02-28028 February 2023 Draft Supporting Statement- Requests to Indian Tribes for Information (3150-0245) ML22318A1272023-01-0303 January 2023 Final OMB Supporting Statement: NRC Form 314 ML22133A0462022-11-10010 November 2022 Response to SRM-M220323: Final Rule-Backfitting and Issue Finality Assessment for Fitness for Duty Drug Testing Requirements ML22133A0522022-11-10010 November 2022 Response to SRM-M220323: Final Rule-Response to Public Comments for Fitness for Duty Drug Testing Requirements SECY-20-0109, Rulemaking: Regulatory Basis for Reporting Requirements for Nonemergency Events at Nuclear Power Plants Rulemaking2022-11-0404 November 2022 Rulemaking: Regulatory Basis for Reporting Requirements for Nonemergency Events at Nuclear Power Plants Rulemaking ML21267A0942022-09-30030 September 2022 Rulemaking: Final Rule: Comment Response Document: Incorporate by Reference American Society of Mechanical Engineers Boiler and Pressure Vessel Code and Operations and Maintenance Code ML21267A0982022-09-30030 September 2022 Rulemaking: Final Rule: Annotated Public Comments Document: Incorporate by Reference American Society of Mechanical Engineers Boiler and Pressure Vessel Code and Operations and Maintenance Code ML22117A2072022-08-16016 August 2022 OMB 3150-0120, Supporting Statement Draft for NRC Form 313 Application for Materials License, and NRC Forms 313A ML22165A1662022-07-20020 July 2022 OMB 3150-0055, Final Supporting Statement for Title 10 of the Code of Federal Regulations Part 75 Safeguards on Nuclear Material - Implementation ML22130A1542022-07-0707 July 2022 Final OMB Supporting Statement for 10 CFR Part 150 Exemptions and Continued Regulatory Authority in Agreement States and Offshore Waters ML22178A0662022-05-24024 May 2022 SRMC-CWDA-2022-00006, Rev. 0, Fiscal Year 2022 Savannah River Site Liquid Waste Facilities Performance Assessment Maintenance Program ML22084A6102022-04-11011 April 2022 NRC Communication with American Board of Health Physics (Abhp) in 2019 Thru 2022 ML21196A1002022-03-0202 March 2022 Rulemaking: Final Rule: Comment Response Document American Society of Mechanical Engineers Code Cases RG 1.84, Rev 39; RG 1.147, Rev 20; and RG 1.192, Rev 4 ML22032A0012022-02-28028 February 2022 Rulemaking; Proposed Rule; Unofficial Redline Rule Language for the Proposed Rule - Regulatory Improvements for Production and Utilization Facilities Transitioning to Decommissioning ML22200A2692022-02-0202 February 2022 5Q1.2-302, Rev. 31, Proceduradiation Monitoring - Water Sampling Analysis ML22021B2992022-01-21021 January 2022 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39, Release of Patients Administered Radioactive Materials, Review and Comment on the Draft Civaderm Device Licensing Guidance, Final Report, January 21, 2022 ML21350A4522021-12-15015 December 2021 Enclosure - Materials RAI Response Clarifications ML21280A1032021-12-0606 December 2021 Updated Biological Assessment of Impacts to Federally Listed Species Under NMFS Jurisdiction for SONGS Decommissioning ML21341A5592021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comments on the Draft Civaderm Device Licensing Guidance, Draft Report, December 1, 2021 ML21341A5642021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comment on Draft Proposed Revision 2 to Regulatory Guide 8.39, Draft Report, December 15, ML21341A5612021-11-29029 November 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on Alpha Dart, Review and Comment on Draft Licensing Guidance Alpha Tau Alpha Dart Manual Brachytherapy, Draft Report, December 15, 2021 ML21294A3422021-11-24024 November 2021 COVID-19 Public Health Emergency Oversight Activities Assessment Phase B Report ML21172A2822021-10-19019 October 2021 Physical Security Requirements for Category II Fuel Cycle Facilities Information Sheet (HALEU Related) ML21286A8002021-10-15015 October 2021 Enclosure 1 - Request for Supplemental Information and Observation for the Model No. CR3MP Package ML21288A1262021-10-14014 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Radionuclide Generator Knowledge and Practice Requirements, Final Report, October 14, 2021 ML21287A6312021-10-14014 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Emerging Radiopharmaceutical Therapy Knowledge Requirements in Theranostics Subcommittee, Final Report, October 14, 2021 ML22012A0702021-10-0404 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Medical Events, Draft Report, October 4, 2021 ML21242A0592021-09-30030 September 2021 Biological Assessment of Impacts to Federally Listed Species Under NMFS Jurisdiction for SONGS Decommissioning ML21259A2182021-09-22022 September 2021 Request for Supplemental Information ML22012A0652021-09-20020 September 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Emerging Radiopharmaceutical Therapy Knowledge Requirements in Theranostics, Draft Report, September 20, 2021 ML22012A0672021-09-0808 September 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Radionuclide Generator Knowledge and Practice Requirements, Draft Report, September 8, 2021 ML21232A5432021-08-20020 August 2021 Advanced Reactors Details Website ML22004A2362021-07-31031 July 2021 CAP88 E-Plan Evaluation Final ML21210A3512021-07-30030 July 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Extravasations, Review and Comments on the Preliminary Evaluation of Radiopharmaceutical Extravasation and Medical Event Reporting, Draft Report, July 30, 2021 ML22004A2312021-07-23023 July 2021 CAP88 E-Plan Eval ML21173A0712021-07-19019 July 2021 Final Supporting Statement for 10 CFR Part 31, (3150-0016), 2021 Information Collection Renewal ML21246A1662021-07-0909 July 2021 Enclosure to Idaho State University License Renewal Application - Request for Supplemental Information ML21085A7472021-04-30030 April 2021 Glwg Agreement State Survey Summary ML21144A1202021-04-0808 April 2021 RA-432-Reclassified 2024-01-19
[Table view]Some use of "" in your query was not closed by a matching "". Category:Technical
MONTHYEARML24018A1152024-01-19019 January 2024 Acu Msrr - Historic and Cultural Resources ML23333A0142023-11-27027 November 2023 Attachment F - Groundwater Tek Inc - Peer Review Study Final-1 ML23333A0172023-11-27027 November 2023 Attachment I - Chin - the Cooling Canal System at the FPL-Turkey-Point Power Station ML23251A0462023-09-30030 September 2023 Technical Report - Review of Documents Related to Tank 12H Grout Formulations ML23192A7672023-08-21021 August 2023 Intercontinental Energy Corporation Final Completion Review Report Review and Approval ML22353A5992023-06-21021 June 2023 Enclosure - NMSS VLSSIR Wg Report and Implementation Guidance ML23097A1712023-05-0808 May 2023 Review of New and Potentially Significant Information for the Holtec Environmental Impact Statement for a Consolidated Interim Storage Facility for Spent Nuclear Fuel in Lea County, New Mexico ML22178A0662022-05-24024 May 2022 SRMC-CWDA-2022-00006, Rev. 0, Fiscal Year 2022 Savannah River Site Liquid Waste Facilities Performance Assessment Maintenance Program ML22021B2992022-01-21021 January 2022 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39, Release of Patients Administered Radioactive Materials, Review and Comment on the Draft Civaderm Device Licensing Guidance, Final Report, January 21, 2022 ML21280A1032021-12-0606 December 2021 Updated Biological Assessment of Impacts to Federally Listed Species Under NMFS Jurisdiction for SONGS Decommissioning ML21341A5592021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comments on the Draft Civaderm Device Licensing Guidance, Draft Report, December 1, 2021 ML21341A5642021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comment on Draft Proposed Revision 2 to Regulatory Guide 8.39, Draft Report, December 15, ML21341A5612021-11-29029 November 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on Alpha Dart, Review and Comment on Draft Licensing Guidance Alpha Tau Alpha Dart Manual Brachytherapy, Draft Report, December 15, 2021 ML21294A3422021-11-24024 November 2021 COVID-19 Public Health Emergency Oversight Activities Assessment Phase B Report ML21172A2822021-10-19019 October 2021 Physical Security Requirements for Category II Fuel Cycle Facilities Information Sheet (HALEU Related) ML21288A1262021-10-14014 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Radionuclide Generator Knowledge and Practice Requirements, Final Report, October 14, 2021 ML21287A6312021-10-14014 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Emerging Radiopharmaceutical Therapy Knowledge Requirements in Theranostics Subcommittee, Final Report, October 14, 2021 ML22012A0702021-10-0404 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Medical Events, Draft Report, October 4, 2021 ML22012A0652021-09-20020 September 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Emerging Radiopharmaceutical Therapy Knowledge Requirements in Theranostics, Draft Report, September 20, 2021 ML22012A0672021-09-0808 September 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Radionuclide Generator Knowledge and Practice Requirements, Draft Report, September 8, 2021 ML21232A5432021-08-20020 August 2021 Advanced Reactors Details Website ML21210A3512021-07-30030 July 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Extravasations, Review and Comments on the Preliminary Evaluation of Radiopharmaceutical Extravasation and Medical Event Reporting, Draft Report, July 30, 2021 ML21085A7472021-04-30030 April 2021 Glwg Agreement State Survey Summary ML21144A1192021-04-0808 April 2021 RA-136-Reclassified ML21144A1202021-04-0808 April 2021 RA-432-Reclassified ML21144A1222021-04-0808 April 2021 SYP-233-Reclassified ML20133J9292020-05-18018 May 2020 Enclosure 1, Technical Evaluation Review of Decommissioning Funding Plan (Publicly Available) ML20128J8322020-05-11011 May 2020 Technical Evaluation Report for the Draft Wir Evaluation for Closure of Wma C at Hanford Site, Washington ML20079E0862020-03-0202 March 2020 Necr B8 Wb (002) ML20079E0892020-03-0202 March 2020 Reply to Arlt Comments 3-2-2020 Draft (002) ML20075A0292020-03-0202 March 2020 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Bylaws Subcommittee, Draft Report, March 2, 2020 ML19297E7912019-10-23023 October 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on the Appropriateness of Medical Event Reporting, Final Report, October 23, 2019 ML19280D1632019-10-0606 October 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Comments on the Draft Evaluation of Training & Experience Requirements for Radiopharmaceuticals Secy Paper, Draft Report, October 6, 2019 ML19297E6942019-08-28028 August 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on the Appropriateness of Medical Event Reporting, Draft Report, August 28, 2019 ML19297E9022019-08-21021 August 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Medical Event Reporting, Review of FY2018, Draft Report, August 21, 2019 ML19296D1202019-08-0808 August 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on ACMUI Institutional Memory, Draft Report, August 8, 2019 ML19106A3672019-07-25025 July 2019 Germanium-68/Gallium-68 Pharmaceutical Grade Generators Licensing Guidance ML19162A2592019-07-22022 July 2019 Technical Analyses of the Hazards of Disposal of Greater-Than-Class C (GTCC) Waste ML19198A2522019-06-20020 June 2019 Alternate Disposal Request - Rail Shipments (License DPR-28, Docket No. 50-271) ML18061A0502018-12-31031 December 2018 U.S. Nuclear Regulatory Commission Staff Responses to Public Comments on Proposed Rule: Amendments to Material Control and Accounting Regulations and Associated Draft Guidance ML18164A0712018-09-20020 September 2018 Us Ecology Idaho Site-Specific Dose Assessment Rev. 3 - TER (Public) ML18204A2142018-08-28028 August 2018 Enclosures 1-6: Pssc Multiple Closure ML18071A4132018-02-27027 February 2018 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Physical Presence Requirements for the Leksell Gamma Knife Icon, Final Report, February 27, 2018 ML18033B0332018-02-0101 February 2018 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Physical Presence Requirements for the Leksell Gamma Knife Icon, Revised Draft Report, February 1, 2018 ML17293A6262017-10-31031 October 2017 Us Sixth National Report for the Joint Convention on the Safety of Spent Fuel Management and on the Safety of Radioactive Waste Management ML17037D1152017-02-0404 February 2017 SONGS ISFSI Only PSP Amendment Nshcd Pages ML17293A2482016-09-13013 September 2016 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Comments on the Yttrium-90 Microsphere Brachytherapy Licensing Guidance, Draft Report, September 13, 2016 ML0420503102004-07-22022 July 2004 Request for Additional Information on License Application and Safety Analyses Report ML0227603052002-09-30030 September 2002 Degradation of the Davis-Besse Nuclear Power Station Reactor Pressure Vessel Head Lessons-Learned Report - Signature Page 2024-01-19
[Table view]Some use of "" in your query was not closed by a matching "". |
Text
U.S. Nuclear Regulatory Commission Advisory Committee on the Medical Uses of Isotopes Subcommittee on Emerging Radiopharmaceutical Therapy Knowledge Requirements in Theranostics Draft Report Submitted on September 20, 2021 Subcommittee Members:
Vasken Dilsizian, M.D.
Ronald Ennis, M.D.
Hossein Jadvar, M.D., PhD (Chair)
Josh Mailman Michael OHara, PhD Zoubir Ouhib NRC Staff Resource: Maryann Ayoade Subcommittee Charge:
The Subcommittee was formed in May 2021, by Dr. Darlene Metter, Chair of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) to:
- To outline the knowledge and specific or specialized practice or policy requirements needed for the safe use and handling of emerging radiopharmaceuticals in theranostics.
- Provide considerations and recommendations to staff.
The Subcommittee reviewed the relevant literature (see reference section) and met virtually four times in July and August 2021 to discuss the charge and propose several considerations in consultation with the NRC staff.
==
Introduction:==
Theranostics is the systemic integration of diagnostic tools (e.g., nuclear imaging) and therapeutic agents (e.g., radiopharmaceuticals) targeted to the same (or similar*) biomolecule (or physiologic parameter*). This concept is the fundamental foundation for precision medicine that has advanced considerably in view of our enhanced understanding of biology, developments in diagnostic technologies, and expansion of therapeutic options. Precision (or personalized) medicine is hoped to improve patient outcome. While theranostics may be applied to a variety of diseases, cancer has been the primary focus in this field (1-4).
Theranostics is a recent term, but it has long been a major player in the history of nuclear medicine, and the list and interest in use of theranostics have been increasing. Early example of theranostics dates back to 1941 when Dr. Saul Hertz from Massachusetts General Hospital, in Boston, MA, treated a patient with Graves disease realizing that radioiodine can target the thyroid tissue based on the basic knowledge that thyroid gland concentrates iodine.
The list below are the currently clinically available theranostics imaging-therapy companion agents, with the biological and disease targets shown in the parenthesis:
- 123I/131I (NaI symporter; thyroid)
- 111In-/90Y-ibritumomab (anti-CD20; lymphoma)
- 18F-NaF/99mTc-MDP; 223RaCl 2 (osteoblastic metastasis; mCRPC)*
- 123I-/131I-MIBG (norepinephrine transporter; pheochromocytoma, paraganglioma)
neuroendocrine tumors NaI=sodium iodide, CD20=cluster of differentiate 20, mCRPC=metastatic castration-resistant prostate cancer, NaF=sodium fluoride, MAA=macroaggregated albumin, MDP=methyl diphosphonate, MIBG=meta-iodobenzylguanidine, DOTA= 1,4,7,10-tetraazacyclododecane-N,N,N,N-tetraacetic acid, DOTATOC=DOTA-d-Phe1-Tyr3-octreotide, DOTATATE= DOTA-DPhe1,Tyr3-octreotate In the near future, theranostics based on prostate specific membrane antigen (PSMA) will be available clinically for the imaging evaluation of prostate cancer (initial staging, biochemical recurrence) and radioligand therapy of metastatic castration-resistant prostate cancer. The imaging agents 68Ga-PSMA-11 and 18F-DCFPyL (PylarifyTM) were approved by the FDA in December 2020 and May 2021, respectively. The favorable results of the randomized phase III VISION clinical trial on the therapy companion - 177Lu-PSMA-617 - has recently been published in the New England Journal of Medicine facilitating an anticipated FDA approval within Q1 of 2022 (5).
Additional theranostics pairs are in the horizon within the next 7 years. These include the following companion agents with the biological and disease targets shown in the parenthesis:
- 225Ac-/227Th-PSMA (alpha RLT; mCRPC)
- 68Ga-/177Lu-NeoB (GRPR; solid tumors)
- 68Ga-/177Lu-FAPI (fibroblast activation protein; multiple cancers)
- 89Zr-/177Lu-girentuximab (carbonic anhydrase IX; clear cell RCC)
- 68Ga-/177Lu-FF58 (integrin a3b5; GBM)
- 18F-/131I-PARPi (DNA repair enzyme Poly-(ADP ribose) polymerase 1; multiple cancers)
RLT=radioligand therapy, GRPR=gastrin-releasing peptide receptor, FAPI=fibroblast activated protein inhibitor, RCC=renal cell carcinoma, GBM=glioblastoma multiforme Challenges:
Despite being a rapidly developing field, theranostics faces several challenges that will need to be addressed adequately in order for it to be fully integrated into clinical medicine (3).
Need for standardized and efficient protocols; formation of interdisciplinary teams; incorporation into clinical guidelines; education and training.
Investment into supporting the supply chain for a steady pipeline of radioisotopes relevant to theranostics; sufficient reimbursement; comparative cost-utility analysis; Research and Development funding.
Additional basic science, pre-clinical, first-in-human, and large prospective clinical trials; evaluation of single, tandem, and combination therapies; development of new applications in oncology and non-oncology arenas.
Subcommittee Specific Comments:
- 1) Radiopharmaceutical (RPT) Healthcare Team:
Depending upon the therapy, the healthcare team administrating the RPT dose may consist of the Authorized User (AU) with appropriate training in theranostics, Certified Nuclear Medicine Technologist (CNMT), Registered Nurse, Radiation Safety Officer (RSO), and Medical Physicist (if available/applicable).
- 2) Authorized User responsibilities:
AU must be present at the time of dose administration; AU is responsible for patient concerns related to RPT, including radiation induced injuries; AU is encouraged to avail themselves of all the latest training information for each new theranostics as they emerge.
- 3) Radiation safety issues:
Non-radiation workers of the healthcare team (e.g. oncology nurse) participating in the procedure may need to wear radiation badges for monitoring as determined by the RSO; therapy should be done in a dedicated and regulatory-approved room appropriate for radioisotope administrations (see Fig. 1); extravasation; patient release criteria (these issues are addressed by other ACMUI subcommittees).
- 4) Regulatory issues:
Radioactive waste management (refer to the facility established guidelines and regulations); ensure that emerging theranostics are performed within the regulatory guidelines.
- 5) Dosimetry:
Dosimetry-based (as opposed to fixed-activity) may play an increasingly important role (6-10); dosimetry-based approach may optimize patient outcome while minimizing
radiation toxicity; no randomized controlled trials to provide level 1 evidence for benefits of dosimetry-based approach; research is needed on impact of combined other nonradioactive therapy agents on RPT biodistribution and radiosensitivity, standardization across clinics, software and medical physicists, development of robust methodology for challenges of surrogate-imaging, microscale radiation effect and daughter distribution (relevant for alpha particles), and research on potential patient benefit versus cost and complexity of logistics; as relevant data becomes mature, AUs should stay abreast of developments in dosimetry.
- 6) Other relevant issues:
Outreach to AUs, healthcare providers, and patients to promote accurate information about safety and efficacy of theranostics (11).
Fig. 1. An illustrative example of a Radiopharmaceutical Therapy clinic room; an attached bathroom is to the left of the picture (not shown).
References:
(1) Jadvar H, et al. Radiotheranostics in Cancer Diagnosis and Management. Radiology 2018; 286:388-400.
(2) Turner JH, et al. An Introduction to the Clinical Practice of Theranostics in Oncology.
Br J Radiol 2018; 91:20180440.
(3) Herrmann K, et al. Radiotheranostics: A Roadmap for Future Development. Lancet Oncol 2020; 21:e146-e156.
(4) Gomes Marin JF, et al. Theranostics in nuclear medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology. Radiographics 2020; 40:1715-1740.
(5) Sartor O, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2021; 385:1091-1103.
(6) Sgouros G, et al. Dosimetry for Radiopharmaceutical Therapy. Semin Nucl Med 2014; 44:172-178.
(7) Lassmann M, et al. The Relevance of Dosimetry in Precision Medicine. J Nucl Med 2018; 59:1494-1499.
(8) Divgi C, et al. Overcoming Barriers to Radiopharmaceutical Therapy (RPT): and Overview from the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy. Int J Radiat Biol 2021; 109:905-912.
(9) Roncali E et al. Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. J Nucl Med 2021; 62:1133-1139.
(10) SNMMI 177Lu Dosimetry Challenge 2021. J Nucl Med 2021; 62:10N.
(11) SNMMI Theranostics Video: https://www.youtube.com/watch?v=Bb8Ts5HWS40 Respectfully Submitted on September 20, 2021 Emerging RPT Knowledge Requirements in Theranostics Subcommittee Advisory Committee on the Medical Uses of Isotopes (ACMUI)
U.S. Nuclear Regulatory Commission (NRC)